Someone forgot to tell the accused yet-to-be identified insider traders of Onyx Pharmaceuticals shares the US Securities and Exchange Commission (SEC) has been paying particularly close attention to stock activity involving biopharmaceutical companies.
Indeed, over the past year, the SEC has frequently been nabbing insider traders, who apparently thought they could outwit the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?